← Back to Clinical Trials
Recruiting NCT06405594

NCT06405594 Neurocognitive Mechanisms of Sentence Production Impairment in Aphasia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06405594
Status Recruiting
Phase
Sponsor University of Maryland, College Park
Condition Aphasia, Acquired
Study Type INTERVENTIONAL
Enrollment 350 participants
Start Date 2024-08-01
Primary Completion 2028-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Language Condition

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 350 participants in total. It began in 2024-08-01 with a primary completion date of 2028-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The proposed research is relevant to public health because stroke is a leading cause of long-term disability among older adults and communication impairments resulting from stroke have a significant negative impact on quality of life. By seeking to better understand post-stroke aphasia, this project lays the groundwork for development of new interventions, and aligns with NIDCD's priority areas 1 (understanding normal function), 2 (understanding diseases), and 3 (improving diagnosis, treatment, and prevention).

Eligibility Criteria

Inclusion Criteria: * At least 18 years of age * Persons with acquired aphasia are defined as those with a language impairment following left hemisphere brain injury (most likely a stroke). * Neurotypical adults need to be either young (ages 18-30 years) or older (\> 60 years) * Native (or primary) speakers of English Exclusion Criteria: * Prior neurological or psychiatric diagnoses or developmental disabilities before the onset of aphasia * do not speak English fluently

Contact & Investigator

Central Contact

Yasmeen Faroqi-Shah, PhD

✉ yfshah@umd.edu

📞 3014054229

Principal Investigator

Yasmeen Faroqi-Shah, PhD

PRINCIPAL INVESTIGATOR

University of Maryland

Frequently Asked Questions

Who can join the NCT06405594 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Aphasia, Acquired. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06405594 currently recruiting?

Yes, NCT06405594 is actively recruiting participants. Contact the research team at yfshah@umd.edu for enrollment information.

Where is the NCT06405594 trial being conducted?

This trial is being conducted at College Park, United States.

Who is sponsoring the NCT06405594 clinical trial?

NCT06405594 is sponsored by University of Maryland, College Park. The principal investigator is Yasmeen Faroqi-Shah, PhD at University of Maryland. The trial plans to enroll 350 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology